List view / Grid view

Franhofer ScreeningPort

Filter the results

 

article

Screening In-Depth Focus 2013

30 July 2013 | By

In this Screening In-Depth Focus: New approaches to cell based assays for high content screening and analysis; Reduce, reuse, recycle: how drug repositioning is finding its niche in drug discovery; Workshop Review: Biochemical assays for screening. Screening roundtable...

article

Drug discovery assays for the histone deacetylase class of enzymes

18 December 2012 | By Sheraz Gul and Gesa Witt, European ScreeningPort GmbH

The histone deacetylase (HDAC) class of enzyme are a group of conserved enzymes known for their ability to remove acetyl groups from lysine residues on histone tails. Since aberrant HDAC enzyme expression is observed in various diseases, there is increasing interest in finding small molecules which function as HDAC enzyme…

article

Discovery and validation of biomarkers for multiple sclerosis

13 December 2011 | By Ole Pless and Sheraz Gul, European ScreeningPort GmbH

Multiple Sclerosis (MS) is an autoimmune disease leading to a chronic inflammation and degeneration of the central nervous system. It is one of the major neurological diseases with approximately 2.5 million suffering patients worldwide. Until now, the underlying mechanisms have not been fully elucidated, but the cause of the disease…

article

Implementing electronic laboratory notebooks to improve the efficiency of pre-clinical drug discovery

13 December 2011 | By Sheraz Gul, Vice President and Head of Biology, European ScreeningPort GmbH

The pre-clinical phase of drug discovery spans a period in the region of five years and requires contributions from multi-disciplinary teams often working at different sites. These teams can generate significant amounts of data which are processed using standard as well as specialist software. The recording of a substantial amount…

article

Reducing attrition in drug discovery: The role of biomarkers

20 June 2011 | By Sheraz Gul, Vice President & Head of Biology, European ScreeningPort GmbH

The development of most diseases is often attributed to the dysfunction of the activities of key proteins involved in biological processes and their modulation by a therapeutic agent is considered to offer the potential to alleviate the disease state.

article

Establishing assays and small molecule screening facilities for Drug discovery programs

16 February 2011 | By Sheraz Gul, Vice President & Head of Biology, European ScreeningPort GmbH

Although many of the marketed small molecule drugs have been discovered by research and development efforts within the pharmaceutical industry, there has been a paradigm shift with external sources increasingly being relied upon to fill their pipelines. This trend is likely to increase and the key pre-clinical activities carried out…

article

Implementation of appropriate assays and HTS technologies in drug discovery

9 May 2010 | By Sheraz Gul, Vice President, European ScreeningPort GmbH

In this article, an overview regarding advances in assay formats for specific target classes and options that should be considered when considering hardware will be given. There has been a significant growth in the assay and automation technologies that are available for compound screening activities and it is essential to…

article

The changing landscape of automation in pre-clinical drug discovery

22 February 2010 | By

Over the past decade we have seen a significant realignment of activities associated with drug discovery and this will continue for a multitude of reasons. Within the pharmaceutical industry we have seen significant changes e.g. a decrease in the numbers of drugs that are being approved by the regulatory authorities…

article

Lab Automation Roundtable

12 December 2009 | By

Participants: Dr Gordon R Alton, President and CEO, Altonyx Consulting / Dr Scott Bowes Scientist, Novartis / Dr Sheraz Gul, Vice President and Head of Biology, European ScreeningPort / Chris Molloy, Vice President of Corporate Development, IDBS

article

Development and implementation of an automated compound screening activities facility

20 March 2009 | By

There has been a continuous move by the large commercially orientated players involved in Drug Discovery to initiate novel methods to increase income streams and productivity. An example of the former has been the acquisition of companies and their drug pipelines and in the case of the latter, rationalisation of…

article

Applying automation in early drug discovery: lessons learnt and future perspectives

29 September 2008 | By

An issue that the drug discovery industry has faced over the past several years has been that whilst the number of targets in their portfolios has increased and the level of investment across all Research & Development functions has risen, the likelihood of discovering suitable chemical starting points for medicinal…